ResApp Health Limited (ASX: RAP), announced today that it was awarded ‘Best Tech IPO/Venture Capital Raising’ at the 2016 Talent Unleashed Awards Asia Pacific Division held at a ceremony last night in Melbourne. Judged by a panel headed by Apple co-founder, Steve Wozniak and Virgin Group founder, Sir Richard Branson, the Awards recognise disruptive entrepreneurs who utilise innovative technology solutions to truly make an impact in their field.
ResApp co-founder and Executive Director, Brian Leedman said, “It was truly an honour to receive this award on behalf of the Company. This recognition is the cumulative effort of everyone involved in helping make ResApp one of the most successful new listings on the ASX and in particular the efforts of The University of Queensland’s Associate Professor Udantha Abeyratne, the technology’s inventor and Dr Tony Keating who has led the Company from its listing last July”.
ResApp will now proceed to the Global Grand Finals event to be held in Sydney on August 18th where each category winner will receive prizes including a bespoke tour of some of Silicon Valley’s leading technology companies.
ResApp also congratulates Associate Professor Abeyratne on being recently named as one of Australia’s Most Innovative Engineers 2016 by Engineers Australia, the leading body for engineering in Australia.
– ENDS –
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has both adult and paediatric clinical studies underway with preliminary results demonstrating accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma and pneumonia in adults. Markets for ResApp’s technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.
For more information on ResApp, visit www.resapphealth.com.au.
ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000
© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.